Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Nicergoline decreases vascular resistance and increases arterial blood flow in the brain,improving the utilization of oxygen and glucose by brain cells. 
Nicergoline has similar vasoactive properties in other areas of the body, particularly the lungs.
Nicergoline is used for vascular disorders such as cerebral thrombosis and atherosclerosis,arterial blockages in the limbs,Raynaud's disease,vascular migraines,and retinopathy.
Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective,and behavioral disorders of older people.
This product is at least as potent as omeprazole in inhibiting gastric acid secretion. In vivo animal models suggest that dexlansoprazole inhibition of gastric acid secretion than H2 receptor antagonist ranitidine, famotidine and omeprazole, but equally effective. Unlike H2 receptor antagonists, both morning and night gastric acid secretion can be inhibited by either morning or night administration. This product can also reduce gastric acid secretion and inhibit the secretion and activity of pepsin. Dexlansoprazole can remove Helicobacter pylori on the gastric mucosa (caused by a bacterial recurrence of peptic ulcer).